Cargando…
In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension
Autores principales: | Yuan, Yuan, Liu, Dan, Zeng, Shaoqing, Wang, Siyuan, Xu, Sen, Wang, Ya, Yu, Ruidi, Gao, Yue, Li, Huayi, Feng, Xinxia, Zhou, Ning, Zhao, Chunxia, Gao, Qinglei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422860/ https://www.ncbi.nlm.nih.gov/pubmed/32800800 http://dx.doi.org/10.1016/j.jinf.2020.08.014 |
Ejemplares similares
-
ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients
por: Zhao, Hong‐Jin, et al.
Publicado: (2021) -
Effects of ACEI and ARB on COVID-19 patients: A meta-analysis
por: Xue, Yang, et al.
Publicado: (2020) -
Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
por: Bertsimas, Dimitris, et al.
Publicado: (2021) -
Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI
por: Ma, Cong, et al.
Publicado: (2012) -
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
por: Huang, Ying, et al.
Publicado: (2020)